PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis.

Abstract

Parathyroid hormone-related protein (1-36) [(PTHrP(1-36)] has been shown to be one of the authentic secretory forms of PTHrP. Human studies employing this peptide have demonstrated that it is equipotent to parathyroid hormone (1-34). This observation, together with the observations that: (1) both peptides employ the same receptors; (2) both bind to this PTH/PTHrP receptor with equal affinity and activate the PTH/PTHrP receptor intracellular signaling pathways with the same efficacy; (3) both peptides are effective anabolic skeletal agents in laboratory animals; and (4) PTHrP is likely to be the endogenous skeletal ligand for the PTH/PTHrP receptor, collectively suggest that PTHrP (1-36) should be as equally effective as PTH(1-34) as an anabolic skeletal agent. In this mini-review, the theoretical basis for the exploration and development of PTHrP(1-36) as a potential therapeutic agent for osteoporosis is considered.

• Authors: A F Stewart
• Journal: Bone (Bone) Vol. 19 Issue 4 Pg. 303-6 (Oct 1996) ISSN: 8756-3282 [Print] United States
• PMID: 8894135 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• PTHLH protein, human
• Parathyroid Hormone
• Parathyroid Hormone-Related Protein
• Proteins

Topics

• Animals
• Bone Density (drug effects)
• Disease Models, Animal
• Humans
• Osteoporosis (drug therapy)
• Parathyroid Hormone (administration & dosage, metabolism, pharmacology, therapeutic use)
• Parathyroid Hormone-Related Protein
• Protein Biosynthesis
• Proteins (administration & dosage, genetics, metabolism, pharmacology, therapeutic use)
• Signal Transduction (drug effects, genetics)
• Tissue Distribution